Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025
October 22, 2025
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
October 10, 2025
October 10, 2025
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
September 23, 2025
September 23, 2025
New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
September 22, 2025
September 22, 2025
New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
September 22, 2025
September 22, 2025
Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to the Board of Directors
September 12, 2025
September 12, 2025
UZEDY® Approved in South Korea
September 10, 2025
September 10, 2025
Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference
September 5, 2025
September 5, 2025
Notice of the 2025 Annual General Meeting Published
August 4, 2025
August 4, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
